Currently browsing category

Infecciones fúngicas

Iatrogenic Cushing’s syndrome induced by posaconazole.

Related Articles
Iatrogenic Cushing’s syndrome induced by posaconazole.
Antimicrob Agents Chemother. 2013 Aug 26;
Authors: Pilmis B, Coignard-Biehler H, Jullien V, Hermine O, Touraine P, Lecuit M, Lortholary O
Abstrac…

No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year «real-life» evaluation.

Related Articles

No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year «real-life» evaluation.

Ann Hematol. 2013 Aug 15;

Authors: Bertz H, Drognitz K, Lübbert M

PMID: 23949313 [PubMed – as supplied by publisher]

In vitro susceptibility of Conidiobolus lamprauges recovered from sheep to antifungal agents.

Related Articles

In vitro susceptibility of Conidiobolus lamprauges recovered from sheep to antifungal agents.

Vet Microbiol. 2013 Aug 2;

Authors: Tondolo JS, Loreto ES, Dutra V, Nakazato L, Paula DA, Zanette RA, Alves SH, Santurio JM

Abstract
Data regarding the susceptibility of Conidiobolus lamprauges is limited and there is no consensus about the optimal treatment for infections caused by Conidiobolus spp. In this context, the objective of this study was to evaluate the in vitro susceptibility of six C. lamprauges strains isolated from sheep conidiobolomycosis to amphotericin B, ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, flucytosine, and terbinafine using the CLSI M38-A2 microdilution technique. Terbinafine was the most active (MIC range <0.06-0.5μg/mL). Resistance or reduced susceptibility was observed for amphotericin B and azole and echinocandin antifungals. Additional studies are necessary to determine the therapeutic potential of terbinafine as monotherapy or in combination therapy with other antifungals.

PMID: 23958402 [PubMed – as supplied by publisher]

New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice.

Related Articles

New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice.

J Infect Dis. 2013 Aug 14;

Authors: Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL

Abstract
The development of treatment protocols with reduced toxicity and equivalent or improved efficacy for Trypanosoma cruzi infection is a high priority. Herein, we tested the effectiveness of benznidazole (BZ) and nifurtimox (NFX), and other prospective drugs in intermittent and combined treatment protocols to cure T. cruzi infection initiated with susceptible and drug-resistant parasite strains. A 40 day course of BZ, NFX or the oxaborale AN4169 cured 100% of mice, while posaconazole (POS), and NTLA-1 (a nitro-triazole) cured ∼90% and 20% of mice, respectively. Reducing the overall dosage of BZ or NFX by using an intermittent (once every 5 days) schedule or combining 5 daily doses of POS with 7 intermittent doses of BZ also provided ∼100% cure. T. cruzi strains resistant to BZ were also found to be resistant to other drugs (POS) and extending the time of treatment or combining drugs did not increase cure rates with these isolates. Thus, dosing schedules for anti-T. cruzi compounds should be determined empirically and compounds targeting different pathways may be combined to yield effective therapies with reduced toxicity. This work also suggests that standard treatment protocols using BZ and NFX may be significantly over-dosing patients, perhaps contributing to the adverse events.

PMID: 23945371 [PubMed – as supplied by publisher]

Feline Nasal Granuloma Due to Cryptoccocus gattii Type VGII.

Feline Nasal Granuloma Due to Cryptoccocus gattii Type VGII.

Mycopathologia. 2013 Aug 13;

Authors: Cardoso PH, Baroni FD, Silva EG, Nascimento DC, Martins MD, Szezs W, Paula CR

Abstract
The aims of this study are to make a more precise identification of the etiologic agent of a nasal granuloma in a cat, to verify the susceptibility to the antifungal drugs: ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole, amphotericin B and the proper treatment. Part of the granuloma’s fragment was removed, added to a saline solution and sent to the Laboratory of Mycology. The solution was then seeded in Sabouraud dextrose agar, and the yeast was primarily identified by the traditional methods. The confirmation of the specie Cryptococcus gattii and its molecular type were performed using the PCR-RFLP molecular techniques. The antifungal susceptibility was verified by using the E-test method, and the cat was treated with itraconazole associated with 5-flucytosine. The isolated strain was identified as C. gattii type VGII and was susceptible to all antifungal drugs tested. The treatment with itraconazole associated with 5-flucytosine led to the cure of granulomatous lesions in the feline after 6 months. The characterization and molecular investigation of this microorganism are relevant because they could help us better understand the epidemiology of the infection and to guide us to treat properly the disease.

PMID: 23943404 [PubMed – as supplied by publisher]

Cutaneous mucormycosis.

Related Articles
Cutaneous mucormycosis.
Skinmed. 2013 May-Jun;11(3):155-9; quiz 159-60
Authors: Skiada A, Petrikkos G
Abstract
Mucormycosis is an invasive fungal infection caused by fungi of the order Mucoral…